The NUP214-ABL1 fusion gene is demonstrated to be amplified as multiple (5–50) episomal copies in 6% of T-cell acute lymphoblastic leukemia (T-ALL) and has been reported as a rare subtype of B-cell precursor (ALL) that could benefit from tyrosine kinase inhibitors (29–31). Here, ABL1 is linked to acute lymphoblastic leukemia.